INHIBITION OF 3'AZIDO-3'DEOXYTHYMIDINE-RESISTANT HIV-1 INFECTION BY DEHYDROEPIANDROSTERONE IN-VITRO

被引:12
|
作者
YANG, JY
SCHWARTZ, A
HENDERSON, EE
机构
[1] TEMPLE UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, PHILADELPHIA, PA 19104 USA
[2] TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19104 USA
关键词
D O I
10.1006/bbrc.1994.1862
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human immunodeficiency virus type 1 (HIV-1) isolated from patients with acquired immunodeficiency syndrome (AIDS) shows resistance to 3'azido-3'deoxythymidine (AZT) after one or two years of treatment. AZT also has significant toxic side effects, further limiting its use in the therapy of HIV-l-infected individuals. Dehydroepiandrosterone (DHEA) has been shown to have a broad spectrum of biological functions, to be bioavailable orally and to be relatively nontoxic. Epidemiological studies provide evidence that reduced serum levels of DHEA are related to the progression of AIDS in HIV-1 infection. DHEA has also been shown to inhibit HIV-1 replication in vitro and block HTV-1 reactivation from chronically infected cell lines. However, there have been no reports on the ability of DHEA to inhibit the replication of AZT-resistant strains of HIV-1. We investigated whether DHEA treatment could inhibit replication of AZT-resistant strains of HIV-1. Addition of DHEA to MT-2 cell cultures infected with either AZT-sensitive or AZT-resistant isolates of HIV-1 resulted in dose-dependent inhibition of HTV-1-induced cytopathic effect and suppression of HIV-1 replication as measured by accumulation of reverse transcriptase activity. At a concentration as low as 50 mu M, DHEA reduced AZT-resistant HIV-1 replication over 50 percent as measured by cytopathic effect and accumulation of reverse transcriptase activity. This study provides evidence that DHEA can inhibit the replication of AZT-resistant as well as wild-type HIV-1. Since the main targets for DHEA are metabolic and cellular signaling pathways leading to HTV-1 replication-activation, DHEA should be effective against multidrug-resistant strains of HIV-1. Combined with recently discovered immunoregulatory properites, the finding that DHEA is able to inhibit replication of both wild-type and AZT-resistant HIV-1 suggests that in vivo DHEA may have a much broader spectrum of action than originally anticipated. (C) 1994 Academic Press, Inc.
引用
收藏
页码:1424 / 1432
页数:9
相关论文
共 50 条
  • [1] INHIBITION OF HIV-1 TRANSMISSION BY INTERFERON AND 3'-AZIDO-3'-DEOXYTHYMIDINE DURING DENOVO INFECTION OF PROMONOCYTIC CELLS
    DUBREUIL, M
    SPORTZA, L
    DADDARIO, M
    LACOSTE, J
    ROOKE, R
    WAINBERG, MA
    HISCOTT, J
    VIROLOGY, 1990, 179 (01) : 388 - 394
  • [2] Inhibition of the initiation of HIV-1 reverse transcription by 3′-azido-3′-deoxythymidine -: Comparison with elongation
    Rigourd, M
    Lanchy, JM
    Le Grice, SFJ
    Ehresmann, B
    Ehresmann, C
    Marquet, R
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (35) : 26944 - 26951
  • [3] RAPID REVERSION OF 3'-AZIDO-3'-DEOXYTHYMIDINE-RESISTANT MUTANTS OF FELINE IMMUNODEFICIENCY VIRUS
    REMINGTON, KM
    NORTH, TW
    PHILLIPS, TR
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 84 - 84
  • [4] 3′-azido-3′-deoxythymidine-resistant mutants of DNA polymerase β identified by in vivo selection
    Kosa, JL
    Sweasy, JB
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (06) : 3851 - 3858
  • [5] ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS-1 (HIV-1) ACTIVITIES OF 3-DEAZAADENOSINE ANALOGS - INCREASED POTENCY AGAINST 3'-AZIDO-3'-DEOXYTHYMIDINE-RESISTANT HIV-1 STRAINS
    MAYERS, DL
    MIKOVITS, JA
    JOSHI, B
    HEWLETT, IK
    ESTRADA, JS
    WOLFE, AD
    GARCIA, GE
    DOCTOR, BP
    BURKE, DS
    GORDON, RK
    LANE, JR
    CHIANG, PK
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (01) : 215 - 219
  • [6] Anti-human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine analogs: Increased potency against 3'-azido-3'-deoxythymidine-resistant HIV-1 strains
    Mayers, D. L.
    Mikovits, J. A.
    Joshi, B.
    Hewlett, I. K.
    Proceedings of the National Academy of Sciences of the United States of America, 92 (01):
  • [7] The 3′-azido group is not the primary determinant of 3′-azido-3′-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1
    Sluis-Cremer, N
    Arion, D
    Parikh, U
    Koontz, D
    Schinazi, RF
    Mellors, JW
    Parniak, MA
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (32) : 29047 - 29052
  • [8] Synergistic antiviral action of ribonucleotide reductase inhibitors and 3'-azido-3'-deoxythymidine on HIV type 1 infection in vitro
    Giacca, M
    Borella, S
    Calderazzo, F
    Bianchi, LC
    DAgaro, P
    Rampazzo, C
    Bianchi, V
    Reichard, P
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (08) : 677 - 682
  • [9] Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance
    Nikolenko, Galina N.
    Delviks-Frankenberry, Krista A.
    Palmer, Sarah
    Maldarelli, Frank
    Fivash, Matthew J., Jr.
    Coffin, John M.
    Pathak, Vinay K.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (01) : 317 - 322
  • [10] HUMAN IMMUNODEFICIENCY VIRUS INHIBITION IS PROLONGED BY 3'-AZIDO-3'-DEOXYTHYMIDINE ALTERNATING WITH 2',3'-DIDEOXYCYTIDINE COMPARED WITH 3'-AZIDO-3'-DEOXYTHYMIDINE ALONE
    SPECTOR, SA
    RIPLEY, D
    HSIA, K
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (06) : 920 - 923